A new analysis released during World Immunisation Week 2026 has sharpened the focus on a persistent weakness in Australia’s health system, highlighting a gap between strong early-stage vaccine research and its translation into real-world outcomes.
The study, published in the journal Vaccine and led by Biointelect in collaboration with Dutch innovation systems expert Linda HM van de Burgwal, examines more than two decades of activity across the sector.
Drawing on 642 patents, 522 publicly funded research grants and 349 clinical trials, the work maps how vaccine innovation progresses through Australia’s system and where momentum is lost.
Australia demonstrates strong capability at the discovery phase, with patent activity rising in bursts, most notably during the COVID-19 pandemic. Public investment is linked to inventive output, particularly in priority disease areas such as influenza, malaria and HIV. Yet the system struggles to convert that activity into locally sponsored clinical trials and later-stage development, with domestic investment only partially translating into tangible downstream outcomes.
Dr van de Burgwal said the issue is not scientific strength but system performance. “Australia has many of the key elements of a high-performing vaccine innovation system, particularly in early-stage research. The challenge is not scientific capability, but how effectively that innovation system supports progression through to later stages. Internationally, systems with stronger coordination tend to achieve better translation outcomes.”
The analysis points to a structural constraint that has long been recognised but has not been sufficiently addressed. Fragmented and inconsistent public datasets limit the ability to track vaccine candidates across the development lifecycle or link research funding to eventual outcomes. Without a coherent view of how projects move from discovery through to deployment, policymakers and investors are left navigating an incomplete picture of impact and return.
Biointelect founder Jennifer Herz said, “World Immunisation Week is a timely reminder that strong vaccines systems don't stop at discovery. This work highlights how difficult it is to track progress and evaluate impact using existing data sources and why improving how we measure progression along the development pathway is critical to ensuring research investment translates into real-world health outcomes.”
To address these limitations, the authors propose adopting a Technology Readiness Level framework alongside more consistent identifiers across datasets. The intent is to create a clearer line of sight from early research investment through to clinical and commercial milestones, and ultimately to public health impact.
The findings also reinforce the importance of situating Australia’s efforts within a global context. Stronger coordination, both domestically and internationally, is framed as a mechanism to improve translation and strengthen Australia’s role in global health security while supporting growth in its biotechnology sector.
The conclusions align with the broader themes set out in Ambitious Australia, which called for a more strategic and connected approach to national research and development. Biointelect plans to extend the conversation later this year at the Australian Vaccines Value Chain Conference in Sydney, where stakeholders will examine how to bridge the gap between discovery and delivery.